Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

New discovery platform for antigen-specific monoclonal antibodies

New discovery platform for antigen-specific monoclonal antibodies

Top-line results from Takeda vedolizumab phase 3 trial on Crohn's disease

Top-line results from Takeda vedolizumab phase 3 trial on Crohn's disease

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Topline, interim results from Celldex Phase 2b EMERGE study of CDX-011 for advanced breast cancer

Topline, interim results from Celldex Phase 2b EMERGE study of CDX-011 for advanced breast cancer

FDA issues Complete Response Letter to Amgen’s sBLA for XGEVA

FDA issues Complete Response Letter to Amgen’s sBLA for XGEVA

Morphotek commences MORAb-004 Phase II study in metastatic colorectal cancer

Morphotek commences MORAb-004 Phase II study in metastatic colorectal cancer

Spectrum signs definitive agreement to acquire Allos

Spectrum signs definitive agreement to acquire Allos

Anti-ceramide antibody may prevent radiation gastrointestinal syndrome

Anti-ceramide antibody may prevent radiation gastrointestinal syndrome

Amgen, UCB commence CDP7851/AMG 785 Phase 3 trial in postmenopausal osteoporosis

Amgen, UCB commence CDP7851/AMG 785 Phase 3 trial in postmenopausal osteoporosis

Lilly announces results of three preclinical studies that focus on c-MET receptor

Lilly announces results of three preclinical studies that focus on c-MET receptor

Safe method for destroying cancer cells using death cap mushroom poison

Safe method for destroying cancer cells using death cap mushroom poison

Combination of cixutumumab and temsirolimus shrinks tumors in patients with Ewing's sarcoma

Combination of cixutumumab and temsirolimus shrinks tumors in patients with Ewing's sarcoma

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

NEJM publishes results from Amgen's brodalumab Phase 2 trial on plaque psoriasis

NEJM publishes results from Amgen's brodalumab Phase 2 trial on plaque psoriasis

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

New method uses E. coli bacteria to engineer human therapeutic glycoproteins

New method uses E. coli bacteria to engineer human therapeutic glycoproteins

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.